Combinational BET and mTOR inhibition unveils EGR1 as acute myeloid leukemia prognostic biomarker

Abstract This study investigated the anti-leukemic potential of BET inhibitors in combination with mTOR inhibitors, focusing on both BET-resistant and BET-sensitive AML cell lines. Our findings reveal a significant suppression of proliferation and induction of apoptosis across all tested cell lines...

Descripció completa

Dades bibliogràfiques

Autors principals:	Marcela Teatin Latancia, Wellington Fernandes da Silva, Elayne Bragança-Jardim, Fernanda Fernandes Terra, Paula Fontes Asprino, Welbert De Oliveira Pereira, Vanessa Candiotti Buzatto, Pedro Alexandre Galante, Lilian Tiemi Inoue, Ana Rita Fonseca, Thais Nascimento Kimmemgs, Celso Arrais-Rodrigues, Vanderson Rocha, Yana Novis, Niels Olsen Saraiva Camara, Ana Paula Lepique, Luiz Fernando Lima Reis, Mariane Tami Amano
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-11-01
Col·lecció:	Scientific Reports
Matèries:	Leukemia mTOR Bromodomain Epigenetics Cancer treatment Inhibitors
Accés en línia:	https://doi.org/10.1038/s41598-025-24366-0
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!